Abstract
Individuals of admixed ancestries (e.g., African Americans) inherit a mosaic of ancestry segments (local ancestry) originating from multiple continental ancestral populations. Their genomic diversity offers the unique opportunity of investigating genetic effects on disease across multiple ancestries within the same population. Quantifying the similarity in causal effects across local ancestries is paramount to studying genetic basis of diseases in admixed individuals. Such similarity can be defined as the genetic correlation of causal effects (radmix) across African and European local ancestry backgrounds. Existing studies investigating causal effects variability across ancestries focused on cross-continental comparisons; however, such differences could be due to heterogeneities in the definition of environment/phenotype across continental ancestries. Studying genetic effects within admixed individuals avoids these confounding factors, because the genetic effects are compared across local ancestries within the same individuals. Here, we introduce a new method that models polygenic architecture of complex traits to quantify radmix across local ancestries. We model genome-wide causal effects that are allowed to vary by ancestry and estimate radmix by inferring variance components of local ancestry-aware genetic relationship matrices. Our method is accurate and robust across a range of simulations. We analyze 38 complex traits in individuals of African and European admixed ancestries (N = 53K) from: Population Architecture using Genomics and Epidemiology (PAGE), UK Biobank (UKBB) and All of Us (AoU). We observe a high similarity in causal effects by ancestry in meta-analyses across traits, with estimated radmix=0.95 (95% credible interval [0.93, 0.97]), much higher than correlation in causal effects across continental ancestries. High estimated radmix is also observed consistently for each individual trait. We replicate the high correlation in causal effects using regression-based methods from marginal GWAS summary statistics. We also report realistic scenarios where regression-based methods yield inflated estimates of heterogeneity-by-ancestry due to local ancestry-specific tagging of causal variants, and/or polygenicity. Among regression-based methods, only Deming regression is robust enough for estimation of correlation in causal effects by ancestry. In summary, causal effects on complex traits are highly similar across local ancestries and motivate genetic analyses that assume minimal heterogeneity in causal effects by ancestry.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was funded in part by the National Institutes of Health under awards R01-HG009120, R01-MH115676. MESA and the MESA SHARe projects are conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with MESA investigators. Support for MESA is provided by contracts 75N92020D00001, HHSN268201500003I, N01-HC-95159, 75N92020D00005, N01-HC-95160, 75N92020D00002, N01-HC-95161, 75N92020D00003, N01-HC-95162, 75N92020D00006, N01-HC-95163, 75N92020D00004, N01-HC-95164, 75N92020D00007, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, UL1-TR-000040, UL1-TR-001079, and UL1-TR-001420, UL1TR001881, and DK063491. Funding for SHARe genotyping was provided by NHLBI Contract N02-HL-64278. Genotyping was performed at Affymetrix (Santa Clara, California, USA) and the Broad Institute of Harvard and MIT (Boston, Massachusetts, USA) using the Affymetrix Genome-Wide Human SNP Array 6.0. The authors thank the other investigators, the staff, and the participants of the MESA study for their valuable contributions. A fill list of participating MESA investigators and institutes can be found at http://www.mesa-nhlbi.org. The Atherosclerosis Risk in Communities study has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, under Contract nos. (75N92022D00001, 75N92022D00002, 75N92022D00003, 75N92022D00004, 75N92022D00005). The authors thank the staff and participants of the ARIC study for their important contributions. The All of Us Research Program is supported by the National Institutes of Health, Office of the Director: Regional Medical Centers: 1 OT2 OD026549; 1 OT2 OD026554; 1 OT2 OD026557; 1 OT2 OD026556; 1 OT2 OD026550; 1 OT2 OD 026552; 1 OT2 OD026553; 1 OT2 OD026548; 1 OT2 OD026551; 1 OT2 OD026555; IAA #: AOD 16037; Federally Qualified Health Centers: HHSN 263201600085U; Data and Research Center: 5 U2C OD023196; Biobank: 1 U24 OD023121; The Participant Center: U24 OD023176; Participant Technology Systems Center: 1 U24 OD023163; Communications and Engagement: 3 OT2 OD023205; 3 OT2 OD023206; and Community Partners: 1 OT2 OD025277; 3 OT2 OD025315; 1 OT2 OD025337; 1 OT2 OD025276. In addition, the All of Us Research Program would not be possible without the partnership of its participants.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Population Architecture using Genomics and Epidemiology (PAGE) gave ethical approval for collection of PAGE data (described in Wojcik et al. Nature 2019). PAGE data are available through dbGaP (phs000356.v2.p1). Ethics committee/IRB of UK Biobank gave ethical approval for collection of UK Biobank data (https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/about-us/ethics). Approval to use UK Biobank individual-level in this work was obtained under application 33297 at http://www.ukbiobank.ac.uk. Ethics committee/IRB of All of Us gave ethical approval for collection of All of Us data (https://allofus.nih.gov/about/who-we-are/institutional-review-board-irb-of-all-of-us-research-program). Approval to use All of Us controlled tier data in this work was obtained through application at https://www.researchallofus.org.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
